Publikationen, an denen er mitarbeitet Ignacio Melero (31)

2024

  1. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391

  2. Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

    Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548

2023

  1. Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma

    Cell Reports Medicine, Vol. 4, Núm. 4

2022

  1. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90

2021

  1. Advances in immunotherapy for hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543

  2. CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

    Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609

  3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9

2020

  1. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469

  2. Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial

    JAMA Oncology

2018

  1. Immunotherapy of hepatocellular carcinoma: Facts and hopes

    Clinical Cancer Research, Vol. 24, Núm. 7, pp. 1518-1524

2017

  1. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

    The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502

2015

  1. Immunological landscape and immunotherapy of hepatocellular carcinoma

    Nature Reviews Gastroenterology and Hepatology, Vol. 12, Núm. 12, pp. 681-700

2014

  1. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins

    Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model

    Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162

2011

  1. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients

    Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142

  2. Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo

    International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386

2009

  1. Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?

    Immunotherapy, Vol. 1, Núm. 5, pp. 845-853

2005

  1. Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8

    International Journal of Cancer, Vol. 116, Núm. 2, pp. 275-281

  2. Gene therapy of cancer based on interleukin 12

    Current Gene Therapy, Vol. 5, Núm. 6, pp. 573-581